Prevention of Ventilation Associated Pneumonia, New Ideas and Better Results

Amir S Matta*
Department of Pulmonary and Critical Care Medicine, Bronx University, USA

Abstract

The ventilation associated pneumonia is one the biggest challenge in the critical care team. It has a high mortality rate and an increase cost of the management. The use of the antibiotics did not show a great improvement in the survival rate. On the other hand, the prevention of ventilation associated pneumonia shows promising results, it improves the survival rate, decease both days of antibiotic use and days in the critical care unit. In the last 10 years, different methods used for the prevention of ventilator associated pneumonia. Some of those methods show a promising results while others need do not.

We reviewed different methods of prevention including oral hygiene, probiotics, cuff pressure control, subglottic secretion drainage, endotracheal cuff, coated endotracheal tube, and the multisystem approach. We review the papers and the data supplement online, and we compared between the different methods in the short outcome, long outcome, length of stay in the ICU, and the cost of the management.

Keywords: Ventilator associated pneumonia; High volume low pressure; Subglottic secretion drainage

Introduction of the Prevention of Ventilation Associated Pneumonia

Ventilator Associated Pneumonia (VAP) is defined as parenchymal infection of the lung occurring in a patient who has been assisted by mechanical ventilation within the past 48 hours, the morbidity and mortality of VAP makes it one of the biggest challenging cases in the critical care unit. VAP incidence is 25% of all critical care unit infectious diseases, and 10-25% of ventilated cases develop VAP, >25% of antibiotics prescribed in ICU are for VAP patients [1], VAP increases the length on mechanical ventilation, and ICU stay, longer hospital length of stay, all of those parameters increases the cost of VAP cases by $40,000 [2]. VAP increase the mortality rate by double [3].

The prevention of VAP shows promising results further than decreasing incidence of VAP. There are several ways has been introduced in the prevention of VAP and become much more complicated than old methods. The sources of the VAP have been identified in several places such as oral cavity [4], subglottic fluid [5], and the gastric mucosa [6].

The endotracheal tube shows an important matter in the development of VAP, as a source of infection and as a reservoir of the infection from the formation of the biofilm on the inner surface of tube [7]. The subglottic fluid, leakage, and micro aspiration has been identified as a source of VAP, different new ways has been introduced to the endotracheal tube to prevent VAP, including new designs of the cup, and suction of the subglottic fluid [8].

We have reviewed the new different ways in the prevention of VAP, in several ways including the incidence of VAP as a primary outcome and the mortality rate, duration of mechanical ventilation, ICU stay as a secondary outcome. Those new methods of VAP prevention include the Oral hygiene, probiotics, cuff pressure control, subglottic aspiration fluid, endotracheal cuff, coated endotracheal tube, and the use of multi system approach.

Oral Hygiene

Dental plaque is a complex and dynamic biofilm that forms on supragingival and subgingival tooth surfaces, oral mucosal surfaces (especially tongue), and dental restorations [9], there are over 700 bacterial species identified in the oral cavity, with more than 400 are present in periodontal pocket [10], Dennesen et al. reveals that absence of adequate salivary flow in intubated patients in ICU may contribute with the development of oropharyngeal colonization, by molecular analysis of the oral and respiratory bacteria in VAP patients, it is shown that 88% of the cases of VAP had an overlap of pathogens in the lung and the oral cavity [4].

The effect of the oral hygiene is proved by Mori et al. there was a significant reduction in the incidence of VAP (episodes of pneumonia per 1000 ventilator days) with oral care comparing with non-oral care (p<0.001, 3.9 vs. 10.4) by using 300 ml weakly acidic water, and swab diluted povidone iodine 3 times a day. There is also a significant reduction in the most pathogenic organisms causing VAP in the oral cavity such as Pseudomonas aeruginosa, Methlin resistant S aureus, and Gram negative bacteria (Enterobacteriaceae, Acinetobacter etc). This effect of the oral hygiene is significant on the early onset of VAP (RR=0.08, 95%CI: 0.02-0.27), but there is no significant decrease in the late onset VAP (RR=0.66, 95%CI: 0.34-1.28) between the oral care and non-oral care [11].

The chlorhexidine is cationic agents that exhibit the bacterial activity through alteration of the membrane causing interferes on the osmotic balance and metabolism. The use of antisepsic oral care for the prevention of VAP (chlorhexidine) was introduced by Genuit et al. in 2001, Genuit studied 95 cases comparing by adding chlorhexidine oral antisepic to the weaning protocol in the prevention of VAP, the results shows a significant reduction of the incidence of VAP, and median duration of mechanical ventilation by 40% (4.5days, p<0.008) comparing with the regular weaning protocol [12].

*Corresponding author: Amir S Matta, Department of Pulmonary and Critical Care Medicine, Bronx University, USA, Tel: +1(347)2516781; E-mail: amir.matta80@yahoo.com

Received October 08, 2014; Accepted February 02, 2015; Published February 05, 2015


Copyright: © 2015 Matta AS. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The effect of use of the chlorhexidine in the prevention of VAP, comparing to regular oral care is controversial. Kusahara et al. studied 96 cases comparing the development of VAP between the use of regular oral care and the use of chlorhexidine, there was no benefit effect from oral care with 0.12% chlorhexidine, the development of VAP in regular oral care was about 16 cases, while the incidence of VAP with the chlorhexidine is 15 cases (p=0.949) [13], that is supported by the meta-analysis of Pineda et al. who fails also to find any statistical clinical benefits of the use of chlorhexidine for the prevention of VAP, (odds ratio of 0.42; 95% confidence interval 0.28-2.11) [14]. But the meta-analysis done by Kola et al. and Chan et al. proving that antiseptic oral chlorhexidine decontamination is effective at preventing of VAP in patients who receive mechanical ventilation for a short period (less than 48h), but has no effect on the overall mortality, duration of the mechanical ventilation or the duration of stay in the critical care [15,16].

The use of the toothbrush and it is effect on the incidence of the VAP was studied by Lorenete et al. He studied 436 ICU patients, divided into two groups, 217 patients received oral care with tooth brushing, and 219 patients received oral care without tooth brushing. He found that there is no statistical significant between the two groups in the incidence of VAP (21 of 217 [9.7%] with tooth brush use vs. 24 of 219 [11.0%] without tooth brush, Odds ratio=0.87; p=0.75) [17], this is also proved by the meta analysis done by Wan-Jie et al. He also proved that oral care with tooth brushing was not associated with decreased mortality rate (RR 0.88, 98% CI 0.70 to 1.10, p=0.26), or decrease the duration of the mechanical ventilation (p=0.31), or antibiotic free days (p=0.29) [18].

We can conclude that the oral hygiene is effective in decreasing the incidence of early VAP but not the late onset VAP, while comparing the use of chlorhexidine and the toothbrush in the oral care to the regular oral care has shown no statistical difference in prevention of VAP.

**Probiotics**

Probiotics are living microbial agents of human origin that are able to tolerate the hostile gastrointestinal environment (acid and bile) such that they ultimately persist in the lower alimentary tract to confer healthy benefits to the host [19]. Probiotics can decrease the inflammatory reaction and improve both the immunological response (the balance between T-helper 1 and T-helper 2 cells), and immunological barrier of the gut [20,21]. The aspiration is one of the pathogenesis of the development of VAP [6], and the bacterial colonization in the oral cavity and gastric fluid are one of the possibilities of the causative organisms for the VAP.

Morrow et al. has shown that there is a significant reduction of the oropharyngeal and gastric colonization after use of nasogastric capsule and oropharynx with Lactobacillus rhamnosus probiotics comparing to placebo, that decrease reflects on the incidence of VAP, that there is a significant decrease in the incidence of VAP between placebo (incidence of 45.2% incidence; 95CI), and probiotics (23.3% incidence; 95% CI; P=0.005), microbiologically, there is a significant reduction of VAP caused by Gram negative organisms (P=0.002), while there is no decrease in the VAP incidence caused by the Gram positive bacteria. Comparing to other methods in the prevention of VAP, the use of probiotics has a significant reduction in antibiotics used for C. difficile causing diarrhea (P=0.002). But regarding other parameters, there is no decrease in the duration of the mechanical ventilation, antibiotic consumption, hospital stay, ICU stay, or the mortality rate [22], that is also supported by I. Siempos et al. who studied 5 randomized controlled trials, he showed that there is a significant decrease in the incidence of VAP between the control group and the group treated with probiotics (689 patients; fixed effect model: OR, 0.61; 95% CI, 0.41-0.91; random effects model: OR, 0.55; 95% CI, 0.31-0.95), also there is no episodes of bacteremia attributable to the probiotic regimen [23].

On the other hand, Gu et al. and Waterlinson et al. have two different meta-analysis of the use of the probiotics in the prevention of VAP. Gu et al. studied 7 randomized control trials showing that there is not a significant reduction in the VAP incidence (OR, 0.82; 95CI, 0.55-1.24; P=0.35). Waterlinson et al. has analyzed 18 randomized controlled trials, showing that there is no significant change with the use of probiotics 1.40 (0.75-2.64) [24,25].

Our opinion about the use of the probiotic in prevention of VAP is still under analysis, as the results are controversial, and statistics did not show a clear results about different parameters such as the incidence, the days in the hospital, the use of the antibiotics.

**Cuff Pressure Control**

The cuff pressure is a challenging problem, as the cuff pressure is important to prevent the leakage of the subglottic fluid and the micro aspiration in the lower respiratory tract causing VAP, but if it is over inflated, it also may cause tracheomalasia, and injury to the tracheal mucosa when it is inflated over the capillary pressure. In addition, the cuff pressure is hard to be maintained with the therapeutic range. Nseir et al. has studied the variation of the endotracheal cuff pressure. He proves that the underinflation of the endotracheal cuff increases over the 8 h recording period, also the presence of sedation is considered a risk of under inflation [26].

The relation between the cuff pressure and development of ventilator associated pneumonia was introduced by Rello et al. who studied 83 intubated cases, undergoing continuous aspiration of subglottic secretions (CASS), he reveals that persistence intra cuff pressure below 20 H2O considered a risk factor for development of VAP (RR=2.57; 95% CI=0.78 to 8.03) [27]. On the other hand, Dullenkopf et al. studied in vitro different pressure levels on the leakage on different tubes of cuff tubes, he proves that the use of tube with polyurethane micro cuff is successful to prevent the leakage when it is inflated pressure around 30 cm H2O [28]. In order to maintain the cuff pressure, Sole et al. has introduced a protocol to maintain the endotracheal cuff pressure within the therapeutic range, by identifying a higher target starting point pressure as the cuff pressure will be decreased by 2 cm H2O when attaching a cufflator to the pilot balloon, then continuous monitoring or an automatic regulating device is attached [29].

The use of the cuff pressure controller shows a significant effect on the prevention of VAP. Nseir et al. has compared the use of a pneumatic device to maintain the tracheal cuff pressure to control group has shown that there was a significant decrease in the bacterial concentration in the tracheal (mean ± SD 1.6 ± 2.4 VS. 3.1 ± 3.7 log10 cfu/ml, p=0.014), and also there is a decrease in VAP incidence (9.8%VS 26.2%; p=0.032). Nseir explains that decrease in VAP incidence is mainly due to the decrease of the aspiration of gastric fluid, as there is a decrease in the pepsin level in the tracheal secretions in the automatic pressure controller group comparing to the control group (p=0.04) [30].

Another study done by Valencia et al. who has studied the effect of the use of the cuff pressure controller in prevention of VAP. Valencia has proved that the cuff pressure is better controlled with automatic device (p=0.001) but this does not affect the incidence of VAP, that is explained by Valencia as they did not systematically perform cultures of oropharyngeal and tracheobronchial secretions and that affect the results of the experiment [31].
We think that inflation and maintaining the cuff pressure around 30 cm H₂O is suitable for preventing the leakage of the subglottic secretion into the trachea and thus decreasing the incidence of the VAP.

**Subglottic Secretion Drainage (SSD)**

The presence of secretion in the subglottic space is proven to be a source of aspiration in the intubated patients [8]. The subglottic secretion leakage occurred between the cuff and the trachea through the longitudinal folds towards the lungs [5,32] or through the micro aspiration of the subglottic secretions; both are proved to be causes of VAP. The subglottic secretion drainage (SSD) is a safe procedure that used to prevent the accumulation of the subglottic secretion.

Lacherade et al. has studied the effect of SSD on the incidence of VAP. A total of 333 cases in a randomized control clinical trial, SSD was associated with decrease in the incidence of the cases of VAP by half, the total number of VAP was 67, 25 of 169 (14.8%) in SSD group, and 42 of 164 (25.6%) in the control group (p=0.02, RR=42.2%, 95%CI, 10.4-63.1%) [33].

Lacherade et al. reveals that there is a decrease in both early and late onset of VAP, the results of the early VAP show that 2 of 169 (1.2%) in the SSD group, and 10 of 164 (6.1%) of the control group (p=0.02), also the incidence of late onset of VAP was decreased, 23 of 126 (18.6%) SSD group, 32 of 97 (33%) of the controlled group (p=0.01) [33].

On the other hand, Bo et al. [34], Wang et al. [35] and Dezfulian et al. [36], published papers show that there is no statistical significant in late onset VAP. Wang et al. reveals that SSD significantly reduced early onset VAP (RR=0.23, 95% CI:0.13-0.43, p<0.0001), while late onset VAP (RR=1.15, 95% CI: 0.51-2.61, p<0.73) [35], Dezfulian suggests that SSD is ineffective in preventing late onset VAP because P. aeruginosa and other Gram negative bacilli, can colonize the trachea without first appearing in the oropharyngeal or subglottic secretions, possibly through adhesion to endotracheal tube biofilm, that indicate that microaspiration may be less relevant to the pathogenesis of pneumonia with these organisms [36]. On the other hand Bo et al. [34] proves that there is a decrease in the incidence of VAP with SSD (p=0.05) and indicates that the efficacy is due to significant reduction caused by Gram-positive cocci and Haemophilus influenzae organisms.

Emilio Bouza et al. shows that the incidence of VAP in post cardiac surgery was decreased with use of continuous SSD comparing with control group, he studied 714 cases. 359 receive continuous SSD, while 331 as a control, for patients those receive MV for more than 48 hours, incidence of early VAP in SSD is 26.7%, while the incidence of VAP in control was 47.5%, (RR=0.40, 95% CI, 0.16-0.99; p=0.04), also there is a significant reduction in the antibiotic use, determined as daily defined doses (DDD), as DDD in SSD group comparing to the control (1,206.5 vs. 1,877.5 ; p<0.001) [37].

The effect of SSD is further than decreasing the VAP incidence; there is a significant shorten of the mechanical ventilation (by 1.55 days), and delayed the onset of VAP (p=0.02, RR=42.2%, 95%CI, 10.4-63.1%) [33].

From previous studies, SSD has proved the efficacy in decreasing the early VAP incidence, days on ventilations and use of antibiotics. Both continuous and intermittent suction have proved their efficacy in decreasing the VAP incidence, while the use of intermittent suction is less side effects regarding the mucosal injury and block the suction system.

**Endo Tracheal Cuff**

The endotracheal tube cuff plays a role in the development of the VAP, as the leakage could happened between the cuff and the tracheal causing pneumonia, that leakage can occur in between the fold of the cuff and the trachea [42]. On the other hand, the use of high pressure cuff impairs the mucosal blood flow and mucosal damage to the tracheal mucosa. High volume low pressure (HVLP) cuff was introduced by Seegobin et al. as a safe procedure that it safes the tracheal mucosa from damage [43]. Unfortunately, HVLP cuff has failed to prevent the leakage of the subglottic fluid [42,44,45].

Different types of Cuff was introduced to achieve both the prevention of the leakage of the subglottic fluid with no impairment of the tracheal mucosa, the use of the low-volume low-pressure cuff (LVLP) was studied by Peter Young et al. He studied different types of tubes in both vivo and in vitro, he shows a significant decrease in the leakage in LVLP tubes (p=0.01) and also there is a decrease in the incidence of VAP comparing with HVLP cuff [45]. Also the use of pressure limited cuff (PLC) such as silicon cuff prevents the leakage of the subglottic secretion into the lungs [42,46]. It also reveals a significant decrease in the incidence of VAP, comparing with HVLP cuffs [44].

Another way to prevent the leakage of subglottic secretion is the micro cuff (polyurethane cuff), the micro cuff tubes with a special cuff design of an ultrathin membrane (7 μm), while the regular cuff membrane is about (50 μM), the polyurethane cuff tubes designed to prevent the longitudinal folds with inflated within the trachea. Dullenkop compares the ultrathin cuff tube with the regular HVLP tube in vitro, he shows the polyurethane cuff tube prevents the leakage of fluid when pressure inside the cuff is set 30cmH₂O [28], Miller et al. studied the effect of ultrathin polyurethane cuff on the VAP incidence. He studied 3207 patients of total 16,223 days of ventilation, the incidence of VAP in Polyurethane cuff tube was 2.8 VAP rate per 1000 ventilator days, while the VAP incidence of VAP in patients with regular endotracheal tube is 5.0 per 1000 ventilator days (p=0.027) [47]. Also, in the cardiac surgery, Polder et al. studied 134 patients, 67 cases with polyurethane cuff and 69 cases as a control, there is a significant reduction in the incidence of VAP (28 vs. 15, p=0.026) [48].

Combination between the polyurethane cuff and the subglottic secretion drainage has magnificent results, that there is a significant decrease in total VAP incidence (p=0.001), early onset VAP (p=0.02) and late onset VAP (p=0.01) with the SSD with polyurethane micro cuff endotracheal tube, comparing with regular endotracheal tube [49].

We can conclude from the previous studies that HVLP failed to decrease the incidence of VAP while both the LVLP cuff and the micro cuff are effective in decreasing the incidence of VAP, by decreasing the leakage between the cuff and the trachea.
Coated endotracheal Tube

The formation of the biofilm is so early after the intubation [50]. And it has a role in the pathogenesis of VAP. The biofilm is a source and reservoir of infection to the lower respiratory tract [7], and a source of the contamination of the respiratory circuits [51], and it is resistance to the effect of the antibiotic [52]. The formation of the ETT biofilm may cause bacterial persistence and impairment of the antibiotic response [53]. The stage of the biofilm is associated with the incidence of VAP, as there is an increased incidence of VAP, at stage IV biofilms when there are floating bacteria and the glycocalyx begin to break down, those can lead to dislodge of the bacteria to the lower respiratory tract causing VAP [54].

The effect of the silver on the development of biofilm shows that the silver coated tubes have an effect in reduction of the formation of the biofilm, as after 16h of intubation there is no formation of the biofilm in the coated tubes, while the biofilm is formed on a non-coated tubes just after 8h (p=0.001) [51,55,56].

The use of the silver coated tubes has no additional adverse effects on the patients while it shows a decrease in the incidence of VAP (in both early onset and late onset pneumonia), comparing with non-coated tubes, that decrease is around 50%, also there is a delayed occurrence of VAP and a decrease in the use of the antibiotic use in the silver coated endotracheal patients comparing to regular endotracheal tube [57,58], but there is no decrease in the ICU stay, hospital stay, or the mortality rate between them [58].

The use of silver coated tubes proves a decrease the incidence of the VAP for both early and late onset by prevention of formation the biofilm on the tube. But the limitation for the use of Silver coated tubes is mainly there is no decrease in other parameters including the days on ventilation, days in ICU.

The Multisystem Approach

Institute of Healthcare Improvement develop the concept “bundle” to improve in the outcome of the patients on ventilator, bundle means A bundle is a structured way of improving the processes of care and patient outcomes: a small, straightforward set of evidence-based practices generally three to five that, when performed collectively and reliably, have been proven to improve patient outcomes.

Rosenthal et al. studied the effect of several factors together in the incidence of VAP, including infection control measures, education, outcome surveillance, process surveillance, feedback of VAP, and performance feedback of infection control process. Those factors placed into a bundle of measures as follows (active surveillance for VAP, adherence to hand hygiene guidelines, semi-recumbent position, daily assessment for waning and weaning protocols, oral care, non-invasive ventilation as possible, oro-tracheal instead naso-tracheal, endotracheal cuff material, cuff pressure control, subglottic secretion, mechanical ventilation shorten, mortality rate, and length hospital stay. The cost of the preventive measures is important. The bundles have shown a decrease incidence with little cost although it did not provide information regarding the effectiveness in prevention of late VAP.

Rate of VAP in 100 patients (5.8 vs. 4.2, RR=0.73(0.64-0.84), p<0.0001), while is no decrease in the mortality rate between the 2 phases [59].

Cachecho et al. studied the effect of the bundle on the rate of VAP in the trauma patients, VAP bundle included head elevation 30 to 45 degrees, mouth hygiene every 6 hours with chlorhexidine, gastrointestinal bleeding prophylaxis, daily assessment of weaning, daily assessment of sedation appropriateness, and daily drug holiday when not contraindicated, Cachecho et al. compares outcome of trauma patients between January 2005 and December 2006 (P1), while P2 from 2007 to 2009, with total cases 954. The results reveals that there is a significant decrease of duration on ventilation in P2 compared to P1 (21.52 ± 15.40 vs. 18.88 ± 10.98, p<0.05), while the VAP rate drops from 7.8/1,000 ventilator days in P1 to 1.4/1,000 ventilator days in P2 (p<0.05) [60].

The use of bundles has shown a promising results in different hospitals and different countries. We think the use of bundles can be applied with effective decrease in the VAP incidence. The important part is the low cost to use the bundle thus it can be applied in most hospitals.

Conclusion

We have reviewed different methods and protocols to decrease the incidence of VAP, some of these measures (such as oral hygiene, endotracheal cuff material, cuff pressure control, subglottic secretion, coated tube) prove effectiveness in decreasing the incidence. Those measures has proved decrease incidence in the early onset pneumonia, while it did not prove to prevent the late onset pneumonia. We recommend more studies in the measures to decrease the late onset pneumonia as well, and more studies regarding the mechanical ventilation shorten, mortality rate, and length hospital stay. The cost of the preventive measures is important. The bundles have shown a decrease incidence with little cost although it did not provide information regarding the effectiveness in prevention of late VAP.

References


19. Guidelines for the evaluation of probiotics in food: report of a joint FAO/WHO working group on drafting guidelines for the evaluation of probiotics in food.


